| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Provoost Jonathan | EVP, Chief Legal Officer | C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER | /s/ Jonathan Provoost, by power of attorney | 03 Feb 2026 | 0001998452 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMRN | Restricted Stock Unit | Award | $0 | +8,013 | $0.000000 | 8,013 | 01 Feb 2026 | American Depositary Shares | 8,013 | $0.000000 | Direct | F1, F2, F3 | |
| transaction | AMRN | Stock Option (right to buy) | Award | $0 | +36,060 | $0.000000 | 36,060 | 01 Feb 2026 | American Depositary Shares | 36,060 | $14.99 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. |
| F2 | On February 1, 2026, the Reporting Person was granted 8,013 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2027, January 31, 2028 and January 31, 2029. |
| F3 | Not applicable. |
| F4 | On February 1, 2026, the Reporting Person was granted an option to purchase 36,060 ADSs under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the first day of each May, August, November and February. |